Goldman Sachs Maintains Neutral on Autolus Therapeutics, Raises Price Target to $4.8
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has maintained a Neutral rating on Autolus Therapeutics (NASDAQ:AUTL) and increased the price target from $3.2 to $4.8.

December 13, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs reaffirmed a Neutral rating on Autolus Therapeutics and raised the price target to $4.8, indicating a positive outlook on the stock's value.
The increase in price target by Goldman Sachs suggests a more optimistic valuation of Autolus Therapeutics, which could lead to increased investor interest and a potential short-term rise in the stock price. The Neutral rating indicates that Goldman Sachs does not see significant overperformance or underperformance relative to the market or sector.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100